In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
New findings from the NEOSTAR trial, published today in Nature Medicine, provide...
The University of Texas MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution’s chief quality and value officer...
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include overlooked proteins from long noncoding RNAs that likely play a functional...
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research...
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company...
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells...